← All organizations
Acquired by Rhone-Poulenc Rorer → Aventis → Sanofi-Synthelabo → Sanofi-Aventis on Jan 1, 1990
Timeline
1920s
- Jan 1, 1928
Rhone Poulenc— Founded
- Jan 1, 1928
Poulenc Freres— Acquired
- Jan 1, 1928
Society of Rhone Chemical Factories— Acquired
1950s
- Jun 1, 1953
ethopropazine— NDA Organization
- Jan 1, 1956
Theraplix— Acquired
1960s
- Jan 1, 1968
Pasteur Merieux— Acquired
1980s
- Jan 1, 1989
Connaught Laboratories— Acquired
1990s
- Jan 1, 1990
Rhone-Poulenc Rorer— Acquired By
2000s
- Jan 1, 2004
Sanofi-Aventis— Now
Drugs by trial phase (15 distinct, 16 trials)
Phase 4 (0 own, 1 via acquisition)
Phase 1 (0 own, 1 via acquisition)
Other trials (0 own, 13 via acquisition)
Indications
Approved for
- Acute Pain
- Amyotrophic Lateral Sclerosis
- Anxiety
- Athetosis
- Basal Ganglia Diseases
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Chronic Pain
- Coronary Artery Disease
- Head and Neck Neoplasms
- Heart Failure
- Hepatolenticular Degeneration
- Hypercalcemia
- Hypersensitivity
- Hypertension
- Neurotic Disorders
- Obsessive-Compulsive Disorder
- Osteitis Deformans
- Osteoporosis, Postmenopausal
- Pain
- Parkinson Disease
- Prostatic Neoplasms, Castration-Resistant
- Pruritus
- Sleep Initiation and Maintenance Disorders
- Somatoform Disorders
- Stomach Neoplasms
- Tuberculosis
- Tuberculosis, Pulmonary
- Urticaria
Marketed drugs (9)
Subsidiaries (5 direct, 6 total across the full acquisition tree)
Details
- Founded
- Lyon, FR Jan 1, 1928
- First NDA
- Jun 1, 1953
- Last known activity
- May 14, 1996
Designations held
- Orphan drug
- Priority review
- Accelerated approval
Notes
formed through merger of: Society of Rhône Chemical Factories (Société Chimiques des Usines du Rhône) and Poulenc-Frères